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Different Doses of Adenoviral Vector Expressing IL-12
Enhance or Depress the Immune Response to a
Coadministered Antigen: the Role of Nitric Oxide1
Juan Jose´ Lasarte, Fernando Jose´ Corrales, Noelia Casares, Ascensio´n Lo´pez-Dı´az de Cerio,
Cheng Qian, Xiaoming Xie, Francisco Borra´s-Cuesta, and Jesu´s Prieto2
Joint immunization with two recombinant adenoviruses, one expressing hepatitis C virus (HCV) core and E1 proteins and another
expressing IL-12 (RAdIL-12), strongly potentiates cellular immune response against HCV Ags in BALB/c mice when RAdIL-12
was used at doses of 1 3 105–1 3 107 plaque-forming units. However, cellular immunity against HCV Ags was abolished when
higher doses (1 3 108 plaque-forming units) of RAdIL-12 were used. This immunosuppressive effect was associated with marked
elevation of IFN-g and nitric oxide in the serum and increased cell apoptosis in the spleen. Administration of N-nitro-L-arginine
methyl ester (L-NAME), an inhibitor of nitric oxide synthase, to mice that received high doses of RAdIL-12 was lethal, whereas
no apparent systemic toxicity by L-NAME was observed in those immunized with lower doses of the adenovirus. Interestingly, in
mice immunized with recombinant adenovirus expressing core and E1 proteins of HCV in combination with RAdIL-12 at low
doses (1 3 107 plaque-forming units), L-NAME inhibited T cell proliferation and CTL activity in response to HCV Ags and also
production of Abs against adenoviral proteins. In conclusion, gene transfer of IL-12 can increase or abolish cell immunity against
an Ag depending of the dose of the vector expressing the cytokine. IL-12 stimulates the synthesis of NO which is needed for the
immunostimulating effects of IL-12, but apoptosis of T cells and immunosuppression ensues when IFN-g and NO are generated
at very high concentrations. The Journal of Immunology, 1999, 162: 5270–5277.
A n abundant body of evidence indicates that immune pro-tection against intracellular pathogens and tumors re-quires the induction of an effective Th1 type of response
(1). Recent studies have shown that IL-12 is the most potent cy-
tokine to direct T cell response toward a Th1 profile stimulating
the development of IFN-g-producing T cells (reviewed in Ref. 2).
In addition, IL-12 enhances cytotoxic cell activity and proliferation
of activated T and NK cells (3). In animal models of infection with
intracellular bacteria, it was found that the pathogen induces the
development of a Th1 response by stimulating macrophages to
produce IL-12 (4). Thus, this cytokine appears to bridge the gap
between innate immune response and the acquisition of specific T
cell-mediated immunity.
Because of these reasons, IL-12 has been proposed as a poten-
tially effective adjuvant in prophylactic and therapeutic vaccines
(2). According to these expectancies, IL-12 was found to be highly
efficient as an adjuvant in different models of infections such as
Leishmania major (5–7), Schistosoma mansoni (8), respiratory
syncytial virus, and pseudorabies virus (9, 10). The beneficial ef-
fects of IL-12 also extend to tumoral immunity (11–13). However,
it has been shown that under certain circumstances and at high
doses, IL-12 inhibits virus-specific cytotoxic T cell activity and is
detrimental to resistance against viral infection (14, 15). On the
other hand, safety studies in rodents and primates revealed that
IL-12 has a rather small therapeutic window (16) and in fact, sig-
nificant adverse effects followed systemic administration of recom-
binant IL-12 in human clinical trials designed to evaluate the an-
titumoral effect of this cytokine (reviewed in Ref. 17).
Although increased circulating IL-12 levels following the injec-
tion of the recombinant cytokine can produce untoward side ef-
fects, the use of adequate doses of gene transfer vectors expressing
IL-12 in association with vectors containing DNA coding for the
Ag might allow continuous low level production of the cytokine at
the right site facilitating immunostimulation without toxicity (18,
19). In a previous work (20), we found that s.c. injection of a
recombinant adenovirus expressing core and E1 proteins of hep-
atitis C virus (HCV)3 (RAdCE1) induces a cytotoxic T cell re-
sponse against a diversity of epitopes from core and against one
specific epitope from E1 (peptide E1 121–135). These studies have
been conducted to investigate the ability of recombinant adenovi-
ruses to induce cellular immunity to HCV Ags in mice as a pre-
vious step to the use of these vectors in primate models of HCV
infection and eventually in humans. To explore whether an adeno-
viral vector expressing IL-12 (RAdIL-12) could enhance cellular
immunity to HCV Ags, in the present work we have analyzed T
cell responses in animals injected with RAdCE1 alone or in com-
bination with different doses of RAdIL-12. Because nitric oxide
has emerged as an important modulator of T cell function (21–26),
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we have also studied the implication of this mediator in the im-
munoregulatory effects produced by the different RAdIL-12 doses
used as adjuvant. Our results indicate that low doses of RAdIL-12
potentiate T cell immunity against HCV Ags whereas high doses
had an inhibitory effect on T cell responses. Nitric oxide was found
to play a critical role in the immunomodulatory effects induced by
IL-12; low levels of NO were required for IL-12-mediated immu-
nostimulation whereas IL-12-mediated immunosuppression was
associated with very high NO production.
Materials and Methods
Generation of recombinant adenoviruses
RAdCE1 under the control of the CMV promoter and recombinant adeno-
virus containing the reporter gene LacZ under the control of the same
promoter were generated as previously reported (20). Recombinant ade-
novirus RAdIL-12 containing the two IL-12 subunits p35 and p40 and
expressing functional IL-12 under control of the CMV promoter was con-
structed as follows: HindIII/SpeI fragment of pBS/p35 containing cDNA of
the p35 subunit of IL-12 was filled in by Klenow and blunt-end ligated into
BamHI-cut pMV100 which carries CMV promoter and poly(A) signal. The
resulting plasmid was digested by HindIII to release p35 expression cas-
sette that was ligated into EcoRI-digested pDE1sp1A by blunt-end ligation
(pDE1sp1A/p40). The NcoI/SmaI fragment of pBS/p40 containing the p40
subunit of IL-12 was cloned into NcoI/EcoRV-cut pCITE-1 carrying IRES
(internal ribosome entry site). The resulting plasmid was digested by EcoRI
to release IRES/p40 fragment which was cloned into EcoRI-cut
pDE1sp1A/p40 from pDE1sp1A/IL-12. BamHI/SalI fragment containing
CMV promoter, p35, IRES p40, and poly(A) signal was cloned into
HindIII-cut adenovirus plasmid pMV60 to form pMV60/IL-12. pMV60
and pJM17 were cotransfected into 293 cells, and plaque was screened to
obtain RAdIL-12.
Peptide synthesis
Peptide E1 121–135 was synthesized manually by the solid-phase method
of Merrifield (27) using the N-fluorenylmethoxycarbonyl alternative (28).
The ninhydrin test of Kaiser et al. (29) was used to monitor every step. At
the end of the synthesis, peptide was cleaved, deprotected, and washed six
times with diethyl ether. The purity of peptide was analyzed by HPLC.
Immunization experiments
Groups of BALB/c mice were immunized i.p. with a combination of dif-
ferent doses of the recombinant adenoviruses RAdCE1, RAd-IL12, and
recombinant defective adenovirus expressing LacZ gene (RAdLacZ) (see
below). Serum samples were extracted at days 3, 6, 11, and 30 after im-
munization to measure IL-12, IFN-g, and humoral responses. Thirty days
after the immunization, mice were sacrificed, and the CTL response against
HCV E1 as well as the intensity and cytokine profile of the Th response
against HCV core were analyzed. In some experiments, 25 mg/kg N-nitro-
L-arginine methyl ester (L-NAME; Sigma Chemical, St. Louis, MO) was
administered to mice i.p. at day 0 and the following 6 days after
immunization.
In vitro cytokine production in response to HCV core protein
Mice were sacrificed 30 days after immunization, and spleen cells were
plated at 0.5 3 106 cells/well in a total volume of 200 ml of culture medium
in the presence or absence of 1 mg of core protein. After 24 h, 50 ml of the
culture supernatants were removed to measure the presence of IL-2 using
a CTL.L bioassay (30). After 48 h of culture, 100 ml of supernatant were
removed to measure IFN-g (ELISA; Genzyme, Cambridge, MA) and IL-4.
IL-4 concentrations in the supernatants were measured using a CT4S bio-
assay (CT4S cells require the presence of IL-4 for their proliferation and
were kindly provided by Dr. W. E. Paul and Dr. C. Watson).
Serum levels of cytokines and in vitro production of IL-12 and
IFN-g by resident peritoneal cells
Serum concentration of IL-12 and IFN-g was measured by commercially
available ELISA assays (Genzyme) according to the manufacturer’s in-
structions. In selected experiments, resident peritoneal cells were obtained
by lavage of the peritoneal cavity of mice 3 days after i.p. administration
of different doses of RAdIL-12. Cells were plated at 1.5 3 105 cells/well
in a total volume of 200 ml of culture medium. After 24 h of culture, IL-12
and IFN-g released to the supernatant were measured by ELISA.
CTL response against E1 121–135
Thirty days after immunization, spleens were removed and homogenized,
and cells were cultured in vitro in 24-well plates at 4 3 106 cells/ml in the
presence of a final concentration of 5 mg/ml peptide E1 121–135. Culture
medium consisted of RPMI 1640 supplemented with 10% FCS, L-glu-
tamine (2 mM), antibiotics, HEPES (5 mM), and 5 3 1025 M 2-ME. Six
days later, cytotoxic activity was measured using a conventional cytotox-
icity assay (31). Assays were done in triplicate at different E:T ratios.
Spontaneous 51Cr release was in all cases below 25% of total release. P815
mastocytoma cells incubated with or without E1 121–135 peptide were
used as targets.
Limiting dilution analysis
Four concentrations of spleen cells (5 3 105, 2.5 3 105, 1.25 3 105, and
0.75 3 105) were placed in 24 replica cultures (for each dilution) in culture
medium in the presence of 10 mg/ml peptide E1 121–135, complemented
with graded numbers of irradiated syngenic spleen cells (3000 rads) to give
a total number of 5 3 105 cells/well (96-well U-bottom plates) in a final
volume of 250 ml of medium. After 6 days of culture at 37°C and 5% CO2,
CTL activity of each individual well was measured using the 51Cr release
assay by transferring 100 ml of each well in a plate containing radiolabeled
P815 cells and peptide E1 121–135, and another 100 ml in a plate with
P815 radiolabeled cells without peptide. After 5 h of culture, 50 ml of
supernatant were removed from each well, and the percentage of lysis was
estimated in a scintillation counter (Topcount, Packard, Meriden, CT). Pos-
itive responses for the individual wells were considered when CTL activity
in the presence of peptide was 15% higher than in the absence of peptide.
Cytotoxic T cell precursor frequencies were calculated on the regression
curve by interpolating the number of responder cells required to give 37%
negative cultures. Only those experiments were considered for which the
data fit in the single-hit model (32) (evaluation according to x2).
Measurement of Abs against adenoviral Ags by ELISA Ab
subtypes
Anti-adenoviral Abs were titrated by ELISA using microtitter wells pre-
viously coated with adenoviral Ags (whole viruses). Plates were incubated
with a solution of PBS containing 1% powdered milk and 0.1% Tween 20
(PBSMT) during 2 h at room temperature to block nonspecific Ab binding.
After removal of the PBSMT, 50 ml of different serum dilutions were
added and incubated at 37°C for 1 h, then washed three times with PBSMT,
and incubated at 37°C for 1 h with a PBSMT solution containing 1/1000
goat anti-mouse whole IgG (Amersham International, Little Chalfont,
U.K.), 1/200 anti-mouse IgG1 or 1/50 anti-IgG2A biotinylated Abs
(Caltag, San Francisco, CA). After three washings with PBSMT, wells
were incubated with a 1/500 dilution of horseradish peroxidase-streptavi-
din (Amersham) at room temperature for 1 h. After three washings with
PBS, the color reaction was started by adding 100 ml of a solution prepared
by mixing: 10 ml of 0.6% acetic acid (pH 4.7); 5 ml of 33% (w/v) hydrogen
peroxidase; and 100 ml of 40 mM water solution of 2,29-azinobis(3-ethyl-
benzothiazoline-6-sulfonic acid) (Sigma). After 30 min, the plates were
read at 405 nm in a Titertek Multiscan MKII (Flow Laboratories, Puteaux,
France).
Measurement of NO in the sera of animals
Nitrite and nitrate were measured using an NOA 280 chemiluminescence
detector following the method recommended by Sievers (Sievers Instru-
ments, Boulder, CO). Serum nitrite and nitrate were reduced to NO by
incubation with 1 N HCl containing 50 mM VCl3 at 90°C. The resulting
NO was measured by the chemiluminescence derived from its reaction
with ozone, according to the following two reactions:
NO 1 O33 NO*2 1 O2
NO*23 NO2 1 hn
Glutathione levels in spleen
Glutathione and glutathione disulfide content was measured by HPLC ac-
cording to the method described by Reed et al. (33). Briefly, 200 ml of the
cytosolic fraction obtained as indicated above were immediately derivat-
ized using 1-fluoro-2,4-dinitrobenzene. Samples were then chromato-
graphed on a 3-aminopropyl-Spherisorb, 20-cm 3 4.6-mm 3 5-mm HPLC
column, equilibrated in 80% methanol. Elution was conducted with 0.5 M
sodium acetate in 64% methanol and followed at 365 nm. Analysis of the
chromatogram was performed with Beckman System Gold software.
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Immunohistochemistry and measurement of apoptosis
Three groups of four mice were immunized i.p. with 1 3 108 plaque-
forming units (pfu) of RAdCE1 in combination with 1 3 108, 1 3 106, or
0 pfu of RAdIL-12. RAdLacZ was administered in such a way that the total
dose of adenovirus in each group of mice was 2 3 108 pfu. One mouse per
group was sacrificed at days 3, 6, 11, and 16. Spleen specimens from the
different groups of animals were cryopreserved in OCT. Measurement of
apoptosis was conducted in samples obtained at day 3 using the In situ Cell
Death Detection Kit, POD (Boehringer Mannheim, Mannheim, Germany)
according to manufacturers instructions. Briefly, tissue sections were fixed
with 4% paraformaldehyde, endogenous peroxidase blocked (0.3% H2O2
in methanol), and permeabilized by incubation with a solution containing
0.1% Triton X-100. Samples were labeled with fluoresceinated nucleotides
by terminal deoxynucleotidyl transferase. Incorporated fluorescein was de-
tected by anti-fluorescein Ab Fab fragments conjugated with peroxidase.
Signal conversion was revealed with a Tris buffer containing diaminoben-
zidine and H2O2. Samples were counterstained with methyl green before
analysis by light microscope. The number of total and apoptotic nuclei was
counted in six randomly selected fields (93292 mm2 per field) in each tissue
section, and the percentage of apoptosis was calculated. A mean of 1530 6
288 nuclei per tissue section were counted. On day 16 after immunization,
spleens from mice immunized with RAdCE1, and different doses of
RAdIL-12 were examined by the indirect immunoperoxidase technique
using fluoresceinated anti-CD41 and anti-CD81 mAbs (Sigma). Incorpo-
rated fluorescein was detected by anti-fluorescein Ab Fab fragments con-
jugated with peroxidase as described above.
Results
Coinjection of RAdCE1 and RAdIL-12: adenoviral gene transfer
of IL-12 modulates T cell response against HCV Ags in a dose-
dependent manner
Five groups of four BALB/c mice were immunized with 1 3 108
pfu of RAdCE1 together with increasing doses of RAdIL-12 (0,
1 3 105, 1 3 106, 1 3 107, and 1 3 108 pfu). RAdLacZ was
injected to complete a total dose of 2 3 108 pfu of recombinant
adenoviruses in all groups of animals. Thirty days after immuni-
zation, spleen cells from these groups of mice were cultured in the
presence or absence of HCV core protein, and the production of
IL-2, IFN-g, and IL-4 was determined.
Fig. 1A shows that the production of IL-2 in response to HCV
core increased progressively in animals that received 1 3 105–1 3
107 pfu of RAdIL-12 in conjunction with RAdCE1, indicating that
within this dose range, codelivery of IL-12-expressing vector and
Ag-expressing vector caused a dose-dependent immunostimula-
tory effect of specific T cell immunity against HCV core. However,
we found that when the dose of RAdIL-12 was increased to 1 3
108 the production of IL-2 in response to HCV core decreased
abruptly. Similarly, the production of IFN-g increased when
RAdIL-12 was given at doses between 1 3 105 and 1 3 107 pfu
but decreased markedly at doses of 1 3 108 pfu (Fig. 1B). The
concentrations of IL-4 in culture supernatants were undetectable in
all groups, indicating that the T helper response against HCV core
induced by codelivery of 1 3 108 pfu of RAdCE1 and RAdIL-12
(1 3 105–1 3 107 pfu) was of the Th1 type. Thus, whereas mod-
erate or low doses of RAdIL-12 stimulate Th1-type responses,
high doses of the vector depress this type of T cell reactivity.
CTL response against HCV E1 121–135 peptide
In a previous work (20), we showed that mice injected with
RAdCE1 developed a CTL response against multiple epitopes
from HCV core and against a single epitope (E1 121–135) from
the HCV envelope protein E1. In the present study, we analyzed
whether different doses of RAdIL-12 (from 1 3 105 to 1 3 108
pfu) could modify the intensity of the CTL response against E1
121–135 induced by a suboptimal dose of RAdCE1 injected si-
multaneously. As shown in Fig. 1C, the magnitude of the CTL
response against E1 121–135 increased progressively with doses
of RAdIL-12 between 1 3 105 and 1 3 107 pfu. However, when
RAdIL-12 was used at the dose of 1 3 108 pfu a marked fall in
CTL activity occurred. Thus, in agreement with results of T helper
responses, we found that doses of RAdIL-12 between 1 3 105 and
1 3 107 pfu had an important adjuvant effect on induction of
specific CTL activity whereas high doses of the IL-12 expressing
vector markedly inhibited CTL generation.
Induction of Abs against adenoviral Ags: Ab subtypes
As observed by others (34, 35), we could not detect Abs against
HCV core in any of the experimental groups of animals, possibly
because this protein is not readily secreted out of the cell. Thus, to
evaluate the effects of different doses of RAdIL-12 on humoral
immunity, we analyzed the changes in Ab production against the
adenoviral vector. Anti-adenovirus Ab titers were determined by
ELISA in serum samples obtained at days 6, 11, and 30 after
immunization with RAdCE1 and different doses of RAdIL-12 as
previously described. Total IgG, IgG1, and IgG2A Ab subtypes
FIGURE 1. Induction of cellular immune responses against HCV Ags
after immunization with RAd-IL12. Production of IL-2 (A) and IFN-g (B)
after restimulation of spleen cells with HCV core protein. C, CTL activity
against peptide E1 121–135. All mice were immunized with 1 3 108 pfu
of RAdCE1 together with different doses (1 3 108, 1 3 107, 1 3 106, 1 3
105, or 0 pfu) of RAdIL-12. Complementary doses of RAdLacZ were ad-
ministered in such a way that all animals received a total dose of 2 3 108
pfu of recombinant adenoviruses. Supernatants were tested after 24 h
(IL-2) and 48 h (IFN-g) of cell culture in the presence or absence of HCV
core protein. Spleen cells were restimulated with peptide E1 121–135 for
5 days, and CTL activity was measured against radiolabeled P815 cells
incubated with or without peptide E1 121–135. An E:T ratio of 20:1 was
used.
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were measured using specific secondary Abs (IgG1 and IgG2A
subtypes were determined only on day 30).
Fig. 2A shows that total IgG Ab titers increased progressively
with increasing doses of RAdIL-12, with the highest values being
observed with the greatest dose of this vector (1 3 108 pfu).
IgG2A (Th1 dependent) Abs followed the same pattern (Fig. 2B)
whereas no IgG1 Abs (Th2 dependent) were detected (Fig. 2C). It
can be concluded that immunization with RAdIL-12 potentiates
humoral response against adenoviral Ags and that this response is
compatible with the induction of a Th1 profile. Interestingly,
whereas high doses of RAdIL-12 resulted in abrogation of T cell
responses, humoral immunity was not suppressed but rather con-
siderably stimulated by high doses of the vector.
Concentrations of IL-12 and IFN-g in serum and in vitro
production of cytokines by resident peritoneal cells
Serum levels of IFN-g and IL-12 were measured on days 3, 6, 11,
and 30 after coimmunization with RAdCE1 and different doses of
RAdIL-12. As represented in Fig. 3A, mice that received 1 3 106
and 1 3 107 pfu of RAdIL-12 showed a small peak of IFN-g in
serum (below 200 pg/ml) between day 3 and day 11 with maximal
values on day 6. In these animals, the levels of circulating IL-12
were undetectable (Fig. 3B) in all determinations. In contrast, a
peak of near 300 pg/ml of IL-12 was found on day 3 in mice
injected with 1 3 108 pfu of RAdIL-12. These mice showed very
high concentrations of IFN-g in serum on days 3 and 6 with max-
imal values around 1200 pg/ml on day 6 (Fig. 3A). These data
indicate that increased systemic levels of IL-12 and marked ele-
vation of IFN-g in serum occur only with high doses of RAdIL-12,
the ones that cause suppression of specific T cell responses. Low
or intermediate doses of the vector cause enhancement of T cell
immunity without increasing circulating IL-12 and with only mild
elevations of IFN-g in serum. From the results obtained in animals
injected with 1 3 108 pfu of RAdIL-12, it seems that increased
production of IL-12 occurs first (peak value on day 3) to be fol-
lowed by enhanced production of IFN-g (peak value on day 6).
We also analyzed the effect of RAdIL-12 on cytokine produc-
tion by resident peritoneal cells (1.5 3 105 cells maintained in
culture for 24 h) by determining the spontaneous release of IL-12
and IFN-g by these cells 3 days after i.p. injection of different
doses (1 3 108, 1 3 107, and 0 pfu) of the vector. IL-12 was
detectable (54 pg/ml) only in peritoneal cell supernatants from
animals immunized with 1 3 108 pfu of RAdIL-12. IFN-g con-
centrations in culture supernatant were 770, 481, and 358 pg/ml
(mean of three mice per group) in animals that received 1 3 108,
1 3 107, and 0 pfu of RAdIL-12, respectively, indicating a dose-
dependent stimulatory effect of RAdIL-12 on IFN-g production.
Production of NO after immunization with RAdCE1 and
different doses of RAdIL-12
We determined the levels of nitrites and nitrates in serum as an
estimation of the amount of NO generated. As represented in Fig.
4, immunization with RAdCE1 in conjunction with high doses of
RAdIL-12 (1 3 108 pfu) resulted in a marked increase in the pro-
duction of NO. In this group, the highest values (211 mM) were
FIGURE 2. Humoral responses against adenoviral particles. Anti-adenoviral total IgG Abs (A), IgG2A (B), and IgG1 (C) were measured by ELISA using
plates coated with whole adenovirus particles. Titration of anti-adenoviral total IgG was carried in all groups of animals at days 6, 11, and 30 after
immunization. As in Fig. 1, all mice were immunized with 1 3 108 pfu of RAdCE1 together with different doses (1 3 108, 1 3 107, 1 3 106, 1 3 105,
or 0 pfu) of RAdIL-12. Complementary doses of RAdLacZ were administered in such a way that all animals received a total dose of 2 3 108 pfu of
recombinant adenoviruses. Measurement of IgG2A and IgG1 was conducted at day 30 after immunization. Results are the mean of three animals per group.
NCS, negative control serum.
FIGURE 3. Levels of IFN-g (A) and IL-12 (B) in the sera at days 6, 11,
and 30 following immunization of animals with RAdCE1 and various
doses of RAdIL-12 or RAdLacZ alone. All mice were immunized with 1 3
108 pfu of RAdCE1 together with different doses (1 3 108, 1 3 107, 1 3
106, 1 3 105, or 0 pfu) of RAdIL-12. Complementary doses of RAdLacZ
were administered in such a way that all animals received a total dose of
2 3 108 pfu of recombinant adenoviruses.
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observed at day 6 and returned to concentrations found in un-
treated mice by day 30 after immunization. Administration of
RAdCE1 together with lower doses of RAdIL-12 (1 3 107 and
1 3 106 pfu) did not induce any detectable rise of NO in serum. In
these groups, the levels were similar to those observed with the
control adenovirus RAdLacZ (0 pfu of RAdIL-12).
Cell apoptosis in the spleen
Both abrogation of T cell responses and increased NO production
were found in mice treated with 1 3 108 pfu of RAdIL-12. Be-
cause NO has been shown to induce apoptosis of T cells (36), we
decided to analyze the presence of apoptotic cells in the spleen of
animals immunized with different doses of RAdIL-12. Mice re-
ceived i.p. 1 3 108 pfu, 1 3 106, or 0 pfu of RAdIL-12 (RAdLacZ
was used as control adenovirus to complete a total dose of 2 3 108
pfu of adenovirus in all animals). The study was performed on day
3 after vector administration. The quantitation of apoptosis was
performed by examination of tissue sections stained using the
TUNEL technique. As shown in Fig. 5, the percentage of apoptotic
cells per field in the spleen is higher in animals treated with 1 3
108 pfu of RAdIL-12 than in the other two groups.
In addition, immunohistochemistry of CD41 and CD81 cells
performed in tissue sections of the spleen obtained on day 16 after
immunization revealed the disappearance of CD41 and CD81 T
cells in mice immunized with RAdCE1 and 1 3 108 pfu of
RAdIL-12 but not in those who received a lower dose of the IL-
12-expressing vector (Fig. 6).
Effect of L-NAME administration on the induction of T cell
responses
In preliminary experiments, we found that administration of L-
NAME (an inhibitor of inducible NO synthase) caused death
within the first 3 days after immunization of all animals that re-
ceived RAdCE1 and 1 3 108 pfu of RAdIL-12. Thus, we inves-
tigated the effect of L-NAME in animals immunized with RAdCE1
(1 3 108 pfu) and lower doses of RAdIL-12 (5 3 107 and 1 3 107
pfu). RAdLacZ (4 3 107 pfu) was used to complete a total dose of
adenovirus of 1.5 3 108 pfu in the group that received the lower
dose of RAdIL-12. Three animals per group were treated by i.p.
injection of 100 mg/day/animal of L-NAME in saline (Table I).
Determinations of NO and IFN-g were done in serum samples on
day 6 after immunization and spleen cells were obtained on day 30
to analyze cellular immune responses.
Mice that received high doses of RAdIL-12 (5 3 107 pfu) ex-
hibited very high serum values of IFN-g and increased NO levels
but survived normally. Similarly to what we found in animals
treated with 1 3 108 pfu of RAdIL-12, administration of L-NAME
caused 100% mortality in the group of mice that received 5 3 107
pfu of RAdIL-12. In contrast, less marked elevations of IFN-g and
NO were found in animals immunized with a lower dose of
RAdIL-12 (1 3 107 pfu). These mice did not experience apparent
toxicity after L-NAME administration. However, in this group L-
NAME produced a reduction of serum IFN-g to undetectable lev-
els and induced a marked inhibition of both CTL activity against
HCV E1 121–135 peptide and proliferative response to HCV core
(Table I). In addition, as shown in Fig. 7, L-NAME caused a sub-
stantial decrease in the production of Abs to adenoviral Ags, both
total IgG and IgG2A Abs. Finally, the immunization protocol with
RAdCE1 plus 1 3 107 RAdIL-12 caused oxidative stress as man-
ifested by low levels of glutathione and total glutathione in the
spleen (Table I). This effect was suppressed, together with specific
immune response to Ags, by treatment with L-NAME.
Discussion
The development of a specific Th1 type of response is critical in
the elimination of intracellular pathogens such as viruses, proto-
zoa, and different types of bacteria (1). IL-12 is produced by APCs
(37) and plays an important role in the induction of Th1 responses
through its ability to prime naive Th0 cells for high IFN-g pro-
duction (3, 38). Thus, IL-12 has been considered to have potential
as an adjuvant in prophylactic and therapeutic vaccines (2).
IL-12 can be applied as a recombinant protein (rIL-12) or by
means of gene transfer methodologies. Administration of rIL-12
may produce systemic toxicity, and in fact this cytokine is known
to have a narrow therapeutic window (16). Gene transfer method-
ologies might favor low level sustained production of the cytokine
at the right site allowing stimulation of T cell responses in the
absence of toxicity (18, 19). Since the immunomodulatory effects
of rIL-12 have been shown to be dose-dependent (14), this dose
dependency might also occur when using gene transfer techniques.
Thus, we have used two adenoviral vectors one expressing HCV
core and E1 (RAdCE1) and the other expressing IL-12 (RAdIL-
12) to study the effects of different doses of RAdIL-12 on the
induced immune response against HCV Ags.
Our results indicate that low and intermediate doses of
RAdIL-12 activate a Th1 type of response against HCV proteins
while high doses resulted in a marked inhibition of the T cell
FIGURE 4. Levels of NO (mM) in the sera at days 3, 6, 11, and 30 after
immunization with RAdCE1 and various doses of RAdIL-12 or RAdLacZ
alone. NCS, negative control serum. All mice were immunized with 1 3
108 pfu of RAdCE1 together with different doses (1 3 108, 1 3 107, 1 3
106, 1 3 105, or 0 pfu) of RAdIL-12. Complementary doses of RAdLacZ
were administered in such a way that all animals received a total dose of
2 3 108 pfu of recombinant adenoviruses.
FIGURE 5. Percent of apoptosis in spleen cells after immunization with
different combinations of recombinant adenoviruses. Mice were immu-
nized i.p. with 1 3 108, 1 3 106 or 0 pfu of RAd IL-12. RAdLacZ was
administered in such a way that the total dose of adenovirus in each group
was 2 3 108 pfu. Apoptosis was measured at day 3 after immunization.
Percentage of apoptosis was calculated from the ratio between the total
nuclei and the apoptotic nuclei in six randomly selected fields from each
tissue section.
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response to HCV Ags with abolition of CTL activity against E1,
and profound decrease of IL-2 and IFN-g production in the pres-
ence of core Ag. The results discussed above are in agreement with
previous data in the literature showing that low doses of rIL-12
activate specific Th1 response in mice infected with lymphocytic
choriomeningitis virus while high doses cause suppression of spe-
cific T cell responses and increased viral load (14).
Of importance, in our model, low and intermediate doses of
RAdIL-12 induced an important enhancement of Th1 responses
without any changes in circulating IL-12 levels, suggesting that
this method can produce immunostimulatory effects without the
risk of side effects derived from increased cytokinemia as observed
in treatments with rIL-12 (16). In our study T cell immunosup-
pression with high doses of RAdIL-12 was associated with con-
siderable elevation in circulating IL-12 on day 3 after immuniza-
tion and with very high levels of IFN-g in serum with the greatest
values being found on day 6 (Fig. 3). The kinetics of these cyto-
kines suggest that IL-12 is expressed early by RAdIL-12-trans-
duced cells and increased production of IL-12 stimulates IFN-g
generation. The stimulatory effect of RAdIL-12 on IFN-g gener-
ation was also evidenced in cell cultures from resident peritoneal
cells. i.p. administration of RAdIL-12 induced detectable produc-
tion of IL-12 by resident peritoneal cells only at the highest dose
tested (1 3 108) but it had a clear stimulatory dose-dependent
effect on the spontaneous production of IFN-g by these cells, in-
dicating that IL-12 below the detection limit can efficiently en-
hance IFN-g production. Since IFN-g was shown to enhance NO
production (15, 39) and NO has recently emerged as a potent reg-
ulator of lymphocyte function (21–26) we have analyzed the role
of this substance in the immunoregulatory effects induced by
RAdIL-12.
We found that production of NO did not change in animals
treated with low or intermediate doses of RAdIL-12 but increased
markedly in mice which received high doses of the vector. These
observations are in agreement with reports indicating that rIL-12
stimulates in a dose-dependent manner the in vitro production of
IFN-g and NO by splenocytes (15). The same authors proved that
anti-IFN-g antibodies were effective in preventing the rise of NO
induced by IL-12. In our system the changes of NO and IFN-g in
serum occur in parallel suggesting a role of IFN-g in NO
generation.
NO has been shown to cause immunosuppression and to reduce
the production of Th1 cytokines when generated in big amounts
(22, 40). In fact, NO has been implicated in the pathogenesis of
immunosuppression caused by S. typhimurium (15) and malarial
(41) infections. Different studies have indicated that Th1 but not
Th2 cells are sensitive to the inhibitory effects of NO (22, 42, 43).
In addition, thymocytes (36) can undergo NO-induced apoptosis
FIGURE 6. Staining of CD41 and CD81 cells in spleen tissue sections from mice immunized with 1 3 108 pfu of RAdCE1 in conjunction with 0 pfu
(A), 1 3 106 pfu (B), or 1 3 108 pfu (C) of RAdIL-12. RAdLacZ was administered in such a way that the total dose of adenovirus in each group was 2 3
108 pfu. Magnification was 320 in all cases.
Table I. Effects of L-NAME administration on survival, immune response to HCV Ags, concentrations of NO and IFN-g in serum and glutathione in
spleen cellsa
Dose of
RAdIL-12 Treatment
% of
Survival
NO in
Serum (mM)b
IFN-g in Serum
(pg/ml)b
Glutathionec
GSH GSSG Total
Frequency of
CTL Precursorsd IL-2 Productione
5 3 107 None 100 (3/3) 65.5 6 10.2 993.6 ND ND ND ND ND
L-NAME 0 (0/3)
13107 None 100 (3/3) 26.5 6 3.5 687.3 15.47 1.58 17.05 1/114548 15503 (3073)
L-NAME 100 (3/3) 13.6 6 2.5 ,38 24.04 2.64 26.73 ,1/106 3994 (1539)
None None 100 (3/3) 13.2 6 3.2 ,38 21.10 1.62 22.62 ND ND
a Two groups of six animals were immunized with 1 3 108 pfu of RAdCE1 in conjunction with either 5 3 107 pfu of RAdIL-12 or 1 3 107 pfu of RAdIL-12 1 4 3 107
pfu of RAdLacZ. Three animals per group were treated by i.p. administration of 100 mg/day/animal of L-NAME in saline. A nonimmunized control group was also included in
these experiments.
b NO and IFN-g was measured in the sera extracted from mice 6 days after immunization.
c Glutathione (GSH) concentrations were measured in spleens of animals extracted 6 days after immunization. GSSG, glutathione disulfide.
d Frequency of CTL precursors against target cells incubated with peptide E1 121–135 was measured 30 days after immunization.
e IL-2 production of spleen cells incubated with HCV core protein (thymidine incorporation of CTLL cells in presence of supernatants of spleen cells incubated with or without
(in parentheses) HCV core protein) was measured 30 days after immunization.
5275The Journal of Immunology
 o
n
 M
arch 30, 2012
w
w
w
.jimmunol.org
D
ow
nloaded from
 
while NO can play a protective role against apoptosis of B lym-
phocytes (44, 45). These data offer an explanation for findings in
the present study which show that animals treated with high doses
of RAdIL-12 and generating elevated levels of NO develop sup-
pression of specific T cell immunity (Figs. 1A, 1B, 1C, and 6)
while humoral response to adenoviral Ags was enhanced in a dose-
related manner with the highest Ab production corresponding to
the greatest dose of RAdIL-12 (Fig. 2). Since the induction of
IgG2A Abs is Th1 dependent and this type of Abs was also stim-
ulated by high doses of RAdIL-12 which appear to be inhibitory
for Th1, we could hypothesize that priming of B cells could occur
during the first days after immunization, before NO generation
reached levels inhibitory for Th1 function.
L-NAME, an inhibitor of inducible NO synthase, did not pro-
duce any apparent toxicity in mice which received RAdIL-12 at
doses of 1 3 107 pfu but caused mortality in all animals treated
with 1 3 108 or with 5 3 107 pfu. In the absence of L-NAME these
mice had very high IFN-g and increased NO values but survived
normally, indicating the already described protective role of NO in
the hypercytokinemic syndrome (46). A relevant finding in this
study relates to the observation that NO, when produced in rela-
tively low amounts, appears to play a critical role in T and B cell
activation in vivo. As indicated in Results, animals immunized
with immunostimulatory doses of RAdIL-12 (1 3 107 pfu) in com-
bination with RAdCE1 and treated with L-NAME failed to develop
T cell proliferation in response to HCV core, exhibited a profound
fall in IFN-g production and the frequency of CTL precursors
against E1 121–135 decreased to less than 1/106 (Table I). More-
over, immunization with the combination of adenoviral vectors in
the presence of L-NAME resulted in a substantial decrease in the
production of anti-adenoviral Abs. These results strongly implicate
NO as a mediator in T cell activation and in the development of
both cellular and humoral immunity after coimmunization with
IL-12. Although NO has been reported to stimulate cytokine pro-
duction in vitro (47, 48) there are no previous data in the literature
showing the inhibitory effect of NO synthase inhibitors on IL-12-
stimulated T and B cell responses in vivo.
In our study we observed a reduction in glutathione concentra-
tion in the spleen in mice treated with RAdCE1 and 1 3 107 pfu
of RAdIL-12, whereas glutathione values similar to controls were
detected in L-NAME-treated mice subjected to the same immuni-
zation procedure (Table I). These findings are consistent with the
presence of NO-mediated oxidative stress in IL-12-treated mice
which might have a role in immune activation. In the same direc-
tion, a recent report has shown that glutathione levels in APCs play
a role in Th1-associated cytokine production (49). Recent data
indicate that oxidative stress participates in activation of both T
and B cells by mechanisms involving induction of thioredoxin and
NF-kB translocation (50).
In conclusion, coadministration of two adenoviral vectors, one
expressing HCV Ags and the other IL-12, resulted in enhancement
of specific T and B cell immune responses to HCV Ags with a Th1
profile when the IL-12-expressing vector was used at low or in-
termediate doses. However, marked suppression of specific T cell
immunity occurred with high doses of IL-12-producing vector. NO
appears to play an important role in both immunostimulatory and
immunosuppressive effects of IL-12. Low doses of recombinant
adenoviruses expressing IL-12 induce potent adjuvant effects with-
out increasing serum levels of IL-12 or IFN-g and thus likely with-
out the side effects of hypercytokinemia which may follow admin-
istration of rIL-12.
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